Actively Recruiting

Phase Not Applicable
Age: 25Years - 40Years
All Genders
NCT07267273

Betamethasone Phonophoresis For Vitiligo

Led by Cairo University · Updated on 2025-12-05

60

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin. Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease. Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients . Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.

CONDITIONS

Official Title

Betamethasone Phonophoresis For Vitiligo

Who Can Participate

Age: 25Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female patients diagnosed with vitiligo.
  • Medically and psychologically stable patients.
  • Good cognitive abilities to understand the requirements of the study.
  • All patients enrolled to the study will have their informed consent.
  • No contraindications to the use of therapeutic ultrasound.
Not Eligible

You will not qualify if you...

  • Pregnancy or lactation.
  • Immunosuppression.
  • Alcohol abuse.
  • History of spontaneous re-pigmentation of lesions.
  • Presence of skin characteristics that may interfere with study assessment.
  • Active bacterial or viral infection.
  • Patients on other immune suppressants and phototherapy.
  • Patients currently participating in any other clinical study.
  • Uncooperative patients.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cairo University Hospital

Cairo, Egypt

Actively Recruiting

Loading map...

Research Team

O

Ola Sabry Abd-Elmaksoud Tarabya, MSc

CONTACT

N

Nisreen Afify Abd-Elrasheed, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here